947248-68-2

Usage

Uses

Used in Medicinal Chemistry:
6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine is used as a building block in the synthesis of pharmaceutical drugs and agrochemicals. Its unique structure allows it to form interactions with biological targets, contributing to the development of new therapeutic agents.
Used in the Development of New Materials:
Due to its chemical properties, 6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine can be utilized in the development of new materials with potential applications in various industries.
Used in Biological Research:
6-Bromo-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine may possess biological activity, and as such, it can be investigated for its potential therapeutic properties. This could lead to the discovery of new treatments for various diseases and conditions.

InChI:InChI=1/C6H5BrN4/c7-4-1-2-5-9-6(8)10-11(5)3-4/h1-3H,(H2,8,10)

Upstream product

• 1010120-60-1 ethyl [(5-bromopyridin-2-yl)carbamothioyl]carbamate 
• 1072-97-5 5-bromo-2-pyridylamine 
• 5470-11-1 hydroxylamine hydrochloride 

Downstream Products

• 1124383-09-0 6-{3-(methyloxy)-4-[(phenylmethyl)oxy]phenyl}[1,2,4]triazolo[1,5-a]pyridin-2-amine 
• 1239954-94-9 6-(2-chloro-5-methoxy-phenyl)-[1,2,4]triazolo[1,5-a]pyridin-2-ylamine 
• 1159826-05-7 3-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzoic acid 
• 1309593-61-0 (6-bromo-[1,2,4]triazolo[1,5-a]pyridin-2-yl)-O-cyanophenyl-amine 
• 1309682-18-5 4-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2,6-dimethylphenol 
• 1309593-62-1 tert-butyl [4-(2-amino[1,2,4]triazolo[1,5-α]pyridin-6-yl)phenyl]carbamate 
• 1159825-94-1 N-[3-(2-amino-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-phenyl]-acetamide 
• 1309682-26-5 4-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-fluorobenzoic acid 
• 1352620-88-2 4-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)-2-methoxybenzoic acid 
• 1352619-58-9 2-cyclopropyl-N-[4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide 
• 1352619-59-0 2-cyclopropyl-N-[4-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)phenyl]acetamide 
• 1352620-71-3 N-[4-(2-amino[1,2,4]triazolo[ 1,5-a]pyridin-6-yl)phenyl]-2-cyclopropyl-acetamide 
• 1352620-06-4 N-(cyclopropylmethyl)-4-(2-{[2-methoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide 
• 1352620-07-5 N-(cyclopropylmethyl)-4-(2-{[2-ethoxy-4-(morpholin-4-ylcarbonyl)phenyl]amino}[1,2,4]triazolo[1,5-a]pyridin-6-yl)benzamide 

Relevant academic research and scientific papers

Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity

RIPK1 plays a key role in the necroptosis pathway that regulates inflammatory signaling and cell death in various diseases, including inflammatory and neurodegenerative diseases. Herein, we report a series of potent RIPK1 inhibitors, represented by compound 70. Compound 70 efficiently blocks necroptosis induced by TNFα in both human and mouse cells (EC50 = 17–30 nM). Biophysical assay demonstrates that compound 70 potently binds to RIPK1 (Kd = 9.2 nM), but not RIPK3 (Kd > 10,000 nM). Importantly, compound 70 exhibits greatly improved metabolic stability in human and rat liver microsomes compared to compound 6 (PK68), a RIPK1 inhibitor reported in our previous work. In addition, compound 70 displays high permeability in Caco-2 cells and excellent in vitro safety profiles in hERG and CYP assays. Moreover, pre-treatment of 70 significantly ameliorates hypothermia and lethal shock in SIRS mice model. Lastly, compound 70 possesses favorable pharmacokinetic parameters with moderate clearance and good oral bioavailability in SD rat. Taken together, our work supports 70 as a potent RIPK1 inhibitor and highlights its potential as a prototypical lead for further development in necroptosis-associated inflammatory disorders.

Triazolopyrimidine and triazolopyridine scaffolds as TDP2 inhibitors

Tyrosyl-DNA phosphodiesterase 2 (TDP2) repairs topoisomerase II (TOP2) mediated DNA damages and causes cellular resistance to clinically used TOP2 poisons. Inhibiting TDP2 can potentially sensitize cancer cells toward TOP2 poisons. Commercial compound P10A10, to which the structure was assigned as 7-phenyl triazolopyrimidine analogue 6a, was previously identified as a TDP2 inhibitor hit in our virtual and fluorescence-based biochemical screening campaign. We report herein that the hit validation through resynthesis and structure elucidation revealed the correct structure of P10A10 (Chembridge ID 7236827) to be the 5-phenyl triazolopyrimidine regioisomer 7a. Subsequent structure–activity relationship (SAR) via the synthesis of a total of 47 analogues of both the 5-phenyl triazolopyrimidine scaffold (7) and its bioisosteric triazolopyridine scaffold (17) identified four derivatives (7a, 17a, 17e, and 17z) with significant TDP2 inhibition (IC50 50 μM), with 17z showing excellent cell permeability and no cytotoxicity.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods of preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to methods o f preparing substituted triazolopyridine compounds of general formula (I) as described and defined herein, as well as to intermediate compounds useful in the preparation of said compounds.

COMBINATIONS FOR THE TREATMENT OF CANCER

The present invention relates to combinations of at least two compounds A and B, compound A being an inhibitor of Mps-1 kinase, and compound B being an inhibitor of an anti-apoptotic protein of the Bcl-2 family. Another aspect of the present invention relates to the use of such combinations as described supra for the preparation of a medicament for the treatment or prophylaxis of a disease, particularly for the treatment of cancer. Another aspect of the present invention relates to the use of an anti- apoptotic protein from the Bcl-2 family as a sensitizer of cells to Mps-1 inhibitors. Another aspect of the present invention relates to the use of the ratio of pro-apoptotic and anti-apoptotic proteins from the Bcl-2 family in a biological sample as a biomarker for a Mps-1 kinase inhibitor treatment.

SUBSTITUTED TRIAZOLOPYRIDINES HAVING ACTIVITY AS MPS-1 INHIBITORS

The present invention relates to substituted triazolopyridine compounds of general formula (I), in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES

The present invention relates to prodrug derivatives of Mps-1 kinase inhibitors, processes for their preparation, and their use for the treatment and/or prophylaxis of diseases.

SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS

The present invention relates to substituted triazolopyndine compounds of general formula (I) : in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.

TRIAZOLOPYRIDINE COMPOUNDS AS PDE10A INHIBITORS

The invention is concerned with triazolopyridine compounds of formula (I) wherein R1, R2 and R3 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhi

UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY

Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.